Browsing Tag
CAMCEVI
2 posts
Foresee Pharmaceuticals licenses MMP-12 pipeline to Primevera in $594m reset to double down on CAMCEVI and injectables
Foresee signs $594 million licensing deal with Primevera Therapeutics to exit MMP-12 R&D and focus on CAMCEVI injectables. Read what this signals for biotech strategy.
January 12, 2026
Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat
Foresee Pharmaceuticals (TPEx: 6576) has reported successful preliminary results from its Phase 1 clinical trial of linvemastat (FP-020),…
October 21, 2024